<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346057</url>
  </required_header>
  <id_info>
    <org_study_id>8616-145</org_study_id>
    <secondary_id>2017-000187-15</secondary_id>
    <nct_id>NCT03346057</nct_id>
  </id_info>
  <brief_title>Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)</brief_title>
  <official_title>A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in American Society of Anesthesiologists (ASA) Class 3 or 4 Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, active comparator-controlled, parallel-group, multi-site, double-blind
      safety trial of sugammadex (MK-8616) for the reversal of neuromuscular blockade (NMB) induced
      by rocuronium or vecuronium in adult ASA Physical Status Class 3 and 4 participants. The
      first primary objective of this study is to characterize the incidence of treatment emergent
      sinus bradycardia, treatment emergent sinus tachycardia, or other treatment emergent cardiac
      arrhythmias after administration of sugammadex. The second primary objective of this study is
      to evaluate the general safety of sugammadex in a population of ASA Class 3 and 4 subjects in
      a surgical setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">April 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Treatment Emergent Sinus Bradycardia After Administration of Sugammadex</measure>
    <time_frame>30 minutes post-administration</time_frame>
    <description>Sinus bradycardia is defined as a heart rate &lt;60 bpm which has also decreased more than 20% compared to the participant's baseline heart rate value, and has been sustained for at least 1 minute after administration of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Treatment Emergent Sinus Tachycardia After Administration of Sugammadex</measure>
    <time_frame>30 minutes post-administration</time_frame>
    <description>Sinus tachycardia is defined as a heart rate &gt;=100 bpm which has also decreased more than 20% compared to the participant's baseline heart rate value, and has been sustained for at least 1 minute after administration of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Treatment Emergent Cardiac Arrhythmias After Administration of Sugammadex</measure>
    <time_frame>30 minutes post-administration</time_frame>
    <description>The percentage of participants experiencing treatment emergent cardiac arrhythmias necessitating intervention (e. g., new or worsening atrial fibrillation, atrial tachycardia, ventricular tachycardia, or ventricular fibrillation) The arrhythmia has been sustained for at least 1 minute after administration of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing One or More Adverse Events After Treatment with Sugammadex</measure>
    <time_frame>Up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Hypersensitivity or Anaphylaxis</measure>
    <time_frame>Up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Sinus Bradycardia or Sinus Tachycardia Necessitating Intervention</measure>
    <time_frame>Up to 7 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">331</enrollment>
  <condition>Reversal of Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 2 mg/kg administered as a single intravenous (IV) dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 4 mg/kg administered as a single IV dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 16 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugammadex 16 mg/kg administered as a single IV dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine + Glycopyrrolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 2 mg/kg</intervention_name>
    <description>Sugammadex 2 mg/kg, administered as a single bolus injection into a fast-running IV line on the day of surgery, for moderate block and reversal in participants receiving the NMBA rocuronium or vecuronium. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.</description>
    <arm_group_label>Sugammadex 2 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 4 mg/kg</intervention_name>
    <description>Sugammadex 4 mg/kg, administered as a single bolus injection into a fast-running IV line on the day of surgery, for deep block and reversal in participants receiving the NMBA rocuronium or vecuronium. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.</description>
    <arm_group_label>Sugammadex 4 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 16 mg/kg</intervention_name>
    <description>Sugammadex 16 mg/kg, administered as a single bolus injection into a fast-running IV line on the day of surgery, for deep block and reversal in participants receiving the NMBA rocuronium</description>
    <arm_group_label>Sugammadex 16 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine + Glycopyrrolate</intervention_name>
    <description>Neostigmine 50 μg/kg plus glycopyrrolate 10 μg/kg, administered as a single bolus injection into a fast-running IV line on the day of surgery, for moderate block and reversal in participants receiving the NMBA rocuronium or vecuronium</description>
    <arm_group_label>Neostigmine + Glycopyrrolate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a body mass index (BMI) &lt; 40 kg/m2.

          -  Is categorized as ASA Physical Status Class 3 or 4, as determined by the Investigator.

          -  Has a planned surgical procedure that requires NMB with either rocuronium or
             vecuronium.

          -  Has a planned surgical procedure (e.g., gastrointestinal, urologic, or laparoscopic)
             that in the opinion of the investigator does not preclude maintenance of moderate or
             deep depth of NMB throughout the case.

          -  If female who is not of reproductive potential, is one of the following: (1)
             postmenopausal; (2) has had a hysterectomy and/or bilateral oophorectomy, bilateral
             salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to
             screening; (3) has a congenital or acquired condition that prevents childbearing; or
             (4) is undergoing surgical sterilization (e.g., hysterectomy or tubal ligation) as the
             planned surgical procedure associated with participation in this study.

          -  If female who is sexually active and of child-bearing potential, agrees to use a
             medically accepted method of contraception through seven days after receiving
             protocol-specified medication. Abstinence (relative to heterosexual activity) can be
             used as the sole method of contraception if it is consistently employed as the
             subject's preferred and usual lifestyle and if considered acceptable by local
             regulatory agencies and Ethics Review Committees/Institutional Review Boards.

          -  Is able to provide (or the participant's legally authorized representative, in
             accordance with local requirements), written informed consent for the trial. The
             participant or legally authorized representative may also provide consent for Future
             Biomedical Research.

        Exclusion Criteria:

          -  Has a pacemaker or automatic implantable cardioverter-defibrillator that precludes the
             assessment of bradycardia or arrhythmias.

          -  Has a medical condition or surgical procedure that precludes reversal of neuromuscular
             block at the end of surgery.

          -  Has a neuromuscular disorder(s) that may affect neuromuscular block and/or trial
             assessments.

          -  Is dialysis-dependent or has severe renal insufficiency (defined as estimated
             creatinine clearance of &lt;30 mL/min.

          -  Has or is suspected of having a personal history or family history (parents,
             grandparents, or siblings) of malignant hyperthermia.

          -  Has or is suspected of having an allergy (e.g., hypersensitivity and/or anaphylactic
             reaction) to study treatments or its/their excipients, to opioids/opiates, muscle
             relaxants or their excipients, or other medication(s) used during general anesthesia.

          -  Has received or is planned to receive toremifene within 24 hours before or within 24
             hours after study medication administration.

          -  Has any condition that would contraindicate the administration of study medication.

          -  Is pregnant, is attempting to become pregnant, or is lactating.

          -  Is currently participating in or has participated in an interventional clinical trial
             (including any other current or ongoing trial with a sugammadex treatment arm) with an
             investigational compound or device within 30 days of signing the informed consent form
             of this current trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Birmingham ( Site 1046)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-996-7383</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Banner Medical Center ( Site 1019)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>520-626-7636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center ( Site 1029)</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>909-558-8493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center ( Site 1001)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>916-734-5048</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital ( Site 1007)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-585-3746</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane University ( Site 1057)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504-988-5068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation ( Site 1005)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504-842-5530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital, Royal Oak ( Site 1034)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>248-898-0833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care ( Site 1022)</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-636-0354</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center ( Site 1058)</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>732-776-3398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital [New Brunswick, NJ] ( Site 1017)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>732-745-8600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mission Hospital - Memorial ( Site 1016)</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>828-213-5987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clin Foundation ( Site 1032)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-445-8281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital ( Site 1004)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140-5103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-707-3325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center ( Site 1033)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-322-2564</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hermann Drive Surgical Center ( Site 1021)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-480-3028</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zablocki VA Medical Center ( Site 1011)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>414384200042429</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Krankenhaus Dornbirn ( Site 1151)</name>
      <address>
        <city>Dornbirn</city>
        <state>Voralberg</state>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4355723032100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch ( Site 1152)</name>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4355223031400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sozialmedizinisches Zentrum Ost - Donauspital ( Site 1150)</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+431288024501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital ( Site 1252)</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4578464818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bispebjerg og Frederiksberg Hospital ( Site 1250)</name>
      <address>
        <city>Copenhagen NV</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4522444802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 1253)</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4535458750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Viborg ( Site 1254)</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4578445212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar Technische Universitaet Muenchen ( Site 1350)</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+498941407206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg Reutlingen ( Site 1352)</name>
      <address>
        <city>Reutlingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4971212003429</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Josephs-Hospitals Warendorf ( Site 1351)</name>
      <address>
        <city>Warendorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492581202233</phone>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arrhythmia, bradycardia, neuromuscular blocking agents, surgery, tachycardia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Vecuronium Bromide</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

